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Abstract
Background: Palliative care is a modality of treatment that addresses physical, psychological and spiritual
symptoms. Dignity therapy, a form of psychotherapy, was developed by Professor Harvey Chochinov, MD in
2005.The aim of the study was to assess the effect of one session of dignity therapy on quality of life in advanced
cancer patients.
Methods: This was a randomized control trial of 144 patients (72 in each arm) randomized into group 1
(intervention arm) and group 2 (control arm). Baseline ESAS scores were determined in both arms following which
group 1 received Dignity therapy while Group 2 received usual care only. Data collected was presented as printed
(Legacy) documents to group 1 participants. These documents were a summary of previous discussions held. Post
intervention ESAS scores were obtained in both groups after 6 weeks. Analysis was based on the intention to treat
principle and descriptive statistics computed. The main outcome was symptom distress scores on the ESAS
(summated out of 100 and symptom specific scores out of 10). The student T-test was used to test for difference in
ESAS scores at follow up and graphs were computed for common cancers and comorbidities.
Results: Of the 144 (72 patients in each arm) patients randomized, 70%were female while 30% were male with a
mean age of 50 years. At 6 weeks, 11 patients were lost to follow up, seven died and 126 completed the study. The
commonly encountered cancers were gastrointestinal cancers (43%, p = 0.29), breast cancer (27.27% p = 0.71) and
gynaecologic cancers (23% p = 0.35). Majority of the patients i.e. 64.3% had no comorbidities.
The primary analysis results showed higher scores for the DT group (change in mean = 1.57) compared to the UC
group (change in mean = − 0.74) yielding a non-statistically significant difference in change scores of 1.44 (p = 0.670;
95% CI − 5.20 to 8.06). After adjusting for baseline scores, the mean (summated) symptom distress score was not
significant (GLM p = 0.78). Dignity therapy group showed a trend towards statistical improvement in anxiety (p =
0.059). The largest effects seen were in improvement of appetite, lower anxiety and improved wellbeing (Cohen
effect size 0.3, 0.5 and 0.31 respectively).
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Conclusion: Dignity therapy showed no statistical improvement in overall quality of life. Symptom improvement
was seen in anxiety and this was a trend towards statistical significance (p = 0.059).
Trial registration: Trial registration number PACTR201604001447244 retrospectively registered with Pan African
Clinical trials on 28th January 2016.
Keywords: Dignity therapy, Palliative care, Quality of life, Advanced cancer patients, Edmonton symptoms and
assessment scale
Background
Cancer by definition is a disease characterized by the ab-
normal proliferation of DNA secondary to somatic mu-
tations which could be primary genetic with
environmental influences [1]. Thirty percent of cancers
are curable if detected early; 30 % are treatable with pro-
longed survival if detected early and another 30 % can
be provided with adequate symptom management and
palliative care [2].
In Kenya, cancer is the third highest cause of mor-
tality (7% of deaths) per year, first in line being infec-
tious diseases e.g. HIV followed closely by
cardiovascular diseases. Estimates in the country have
shown that new cases are up to 39,000 per year with
more than 27,000 deaths per year of whom majority
are less than 70 years of age [3]. Most cancer patients
present late to health facilities due to various factors
which include both psychosocial and economic factors
[4]. Treatment dynamics in these patients have moved
from purely curative to palliative care models primar-
ily to improve quality of life.
Targeted psychotherapy namely dignity therapy has
been utilized in this study [5–8]. Dignity therapy is by
definition a “unique, individualized psychotherapy that
allows patient to revisit their lives and find meaningful
events, persons and experiences hence maintaining their
dignity” [5]. Studies have illustrated good outcomes in
lowering depression, anxiety and grief in these patients
in addition to numerous other benefits [5, 6, 9].
The inventor of Dignity therapy is a well-known pro-
fessor of psychiatry known as Dr. Harvey Max Chochi-
nov [5, 9, 10] who developed it as a means of assisting
people dealing with the imminent end of their lives. The
therapy includes 10 core questions [5, 6, 9] that address
the most important accomplishments, lessons in life,
hopes and dreams for loved ones and many more. (See
Additional file 1). The trained therapist leads the patient
through a session with open-ended questions usually be-
tween 30 and 60min after rapport is established. The
patients are free to discuss their lives events freely and
the conversation is recorded, transcribed, edited and
returned within a few days. The therapy creates some-
thing that will transcend the patient’s death and extend
his or her influence across time.
There have been numerous trials with some efficacy
studies pioneered by Chochinov himself [2, 5, 9] who
conducted the largest known study to date in
2011.Other smaller studies by Hall et al. [11–14], Juliao
et al. [5, 12, 15–17] etc. have been conducted with the
most recent one being in 2017 [18–20].
Notably, the largest study [9] which included 441 pa-
tients divided in 3 groups, was among the few powered
to detect small or moderate outcomes in the study. In
this study, there were no statistically significant differ-
ences in primary outcomes in patients receiving DT as
compared to the other two groups. In the newer studies
from 2016 to 2018, most had improvement in primary
outcomes [12, 17].
None of the studies addressed Quality of life as a pri-
mary outcome which the basis of this study.
The tool used in evaluation of quality of life outcomes
was the revised Edmonton symptom assessment scale
(see Additional file 1). This tool has been validated in
previous studies [21–25] and was in use in AKUHN
(Agakhan University Hospital, Kenya) at the time of the
study.
Methods
This study adheres to CONSORT guidelines.
The Primary Objective of the study was to compare
dignity therapy vs usual care on quality of life of ad-
vanced cancer patients undergoing palliative care. Qual-
ity of life was measured using the Edmonton symptom
scale (ESAS).
This was a parallel design randomized control trial set
at the Aga Khan University hospital, which is a private
referral hospital located in Kenya’s capital city Nairobi.
Patients were recruited from the inpatient hospital set-
ting and outpatient oncology clinics, which included sur-
gical oncology, medical oncology and radiation
oncology. The study population included all English-
speaking adults aged between 18 and 65 years with ad-
vanced cancers (stage 3 and 4) at Aga Khan University
hospital Nairobi.
All patients with any acute illness that was easily treat-
able/reversible (in addition to the underlying cancer)
were excluded since they could skew the results espe-
cially on recovery.
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This study was a superiority trial with a 1:1 parallel de-
sign. The power was set at 80% with a set p-value of
0.05. The sample size was 144, 72 per arm.
Recruitment was conducted by the principal inves-
tigator who was assisted by triage nurses allocated to
the respective clinics. Informed consent was obtained
from each patient and patients who were cognitive
but could not sign due to disability or otherwise
used thumb prints. Simple randomization was car-
ried out using a computer generated randomization
list with the help of a statistician into two groups.
The first was the intervention arm where an ESAS
form was filled prior to dignity therapy (and their
usual care). The second group i.e. the control group
had the ESAS filled before they received their usual
care.
There was single blinding i.e. the patients only. The
outcome assessors (counsellors) and the primary investi-
gator were not blinded.
Trained counsellors/primary investigator through oral
interviews, which were tape-recorded and/or transcribed
on paper, administered dignity therapy. This was a single
session; no additional sessions were given during the
course of the study. This is mainly due to the fact that a
pre-test had been done in the quality controlled sessions
involving the counsellors and had been found to be ap-
propriate for the study. The sessions were conducted in
a private setting i.e. room in clinic or bedside by the pro-
vider who delivered these services at least once to the
patients in the intervention arm. The counsellors first
introduced themselves, established rapport and adminis-
tered the pre-intervention tool i.e. ESAS within an aver-
age of 10 min. This was before the actual intervention
involving Dignity therapy.
Dignity therapy(intervention) sessions were then
conducted and since majority of the patients were
stable, time taken was on average 30–60 min accord-
ing to previous studies [5, 6, 9, 26]. The counsellors
were trained 3 months prior to the study with prac-
tice sessions involving live patients. The training in-
volved a brief of dignity therapy and videos of
professional dignity therapists conducting the inter-
views. Quality control measures were undertaken by
using the standardized template to conduct interviews
i.e. involving Dignity therapy. This was the printed
version of Chochinov’s protocol. These sessions were
tape recorded (before the start of the study and after
the study was conducted), selected at random and
reviewed by the primary investigator to ensure
standardization was occurring.
Follow-up
This was set at 6 weeks (as per previous studies; some
studies had short intervals of up to 7 days immediately
post therapy) [5, 9, 15, 18, 20, 26, 27]. Follow-up inter-
views were conducted via Physical review or telephone
interview (has been validated in feasibility studies [5, 9,
15, 18, 20, 26, 27] and conducted. The follow-up inter-
views allowed the participants in the intervention arm
(Group 1) to review the typed legacy document depict-
ing the previous session on Dignity therapy and there-
after fill the ESAS form. The control arm filled the ESAS
form as well.
Patients who were lost to follow up or died in the
course of the study were included in the analysis as per
the intention to treat principle.
Data analysis
Categorical data was presented as frequencies and per-
centages while continuous data was presented as mean
and standard deviations. Normality tests were done on
the continuous data using Shapiro Wik tests. Explora-
tory subgroup analysis was performed for gender and
age groups (below 45 years and above 45 years). Fre-
quency distributions for types of cancers and comorbidi-
ties by age and gender were presented in tables and
Charts.
The primary outcome was measured as summated and
symptom specific ESAS scores at follow up. Symptom
specific scores range from 0 to 10, with lower scores sig-
nifying better symptom outcomes. The Summated scores
were calculated by adding scores on each ESAS item to
generate one score out of 100.
To adjust for possible imbalances in baseline ESAS mea-
sures, multivariate analysis i.e. a general linear model (GLM)
was conducted to determine a statistically significant differ-
ence between the intervention and control groups (fixed fac-
tors) on mean symptom distress score while controlling for
baseline ESAS scores (continuous covariate).
Results
Participant flow
Participants were recruited between August 2016 and
March 2017. About 205 patients were assessed for eligi-
bility, out of which 61 did not meet the eligibility cri-
teria. Reasons for ineligibility included ongoing acute
illness (n = 6), predominant communication in Kiswahili
(Kenya’s official language) (n = 38), refusal to participate
in the study (n = 17) and 9 who were acutely ill. Of the
remaining 144 that were eligible, 72 were randomized to
the intervention group, and 72 to the control group. Of
the ones randomized, five were lost to follow-up in the
Dignity therapy group while two died before post assess-
ment. In the usual care group, six were lost to follow-up
and five died before post assessment. Only 126 patients
completed the study. One hundred and fourty three par-
ticipants (one was excluded due to repetitive enrollment)
were included for primary analysis; 72 in the
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intervention group, and 72 in the control group. We in-
cluded the ones who died or were lost to follow-up as
per the intention to treat principle, with one excluded
due to repetition. Recruitment ended once the target
number of patients was reached (Fig. 1). Follow-up as-
sessments were conducted after 6 weeks after which trial
was concluded.
Baseline clinical and demographic characteristics
A descriptive comparison of intervention and control
groups did not reveal differences with regard to clinical
or demographic characteristics. The mean age of partici-
pants was 50.5 and 52.5 years in the intervention and
control group respectively. More females participated in
the study compared to men in both groups. Breast can-
cer was the most common in both groups while stage IV
disease was the most prevalent in both groups receiving
palliative care. The most common form of treatment as
per the time of participant recruitment was chemother-
apy followed by radiotherapy, combined radiotherapy
and chemotherapy with surgery and hormonal treatment
having the lowest number of patients. A graphical repre-
sentation is shown in Figs. 2 and 3.
Primary outcomes
The Student t-test was utilized first before adjusted ana-
lysis using the general linear model (GLM). The primary
analysis results showed higher scores for the DT group
(change in mean = 1.57) compared to the UC group
(change in mean = − 0.74) yielding a non-statistically sig-
nificant difference in change scores of 1.44 (p = 0.670;
95% CI − 5.20 to 8.06). Therefore, dignity therapy incor-
porated in routine clinical care was not shown to statisti-
cally improve the quality of life of these patients as
compared to routine care only.
Generalized linear models were used to adjust the
baseline scores in order to find associations in mean
scores at 6 weeks follow up. After adjusting the baseline
scores, the results showed no statistically significance in
summated post assessment scores (p = 0.127).
Symptom specific analysis
An independent student’s t-test evaluating symptoms in
the two groups at baseline and at 6 weeks was con-
ducted. Statistically significant differences within individ-
ual groups were noted in anxiety (Dignity group-p =
0.005) and nausea (Control group, p = 0.051) in usual
therapy group. This suggested that dignity therapy
Fig. 1 Bar graph illustrating distribution of malignancies among study participants.
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Fig. 2 Bar graph illustrating staging of different malignancies among study participants.
Fig. 3 Are probability plots for mean follow up scores and the mean difference in follow up scores between intervention and control
groups respectively.
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improved anxiety in the intervention group and patients
receiving usual care had overall reductions in nausea
(likely due to medications given by primary care giver).
Discussion
This single center randomized controlled trial assessed
the effect of dignity therapy on quality of life in ad-
vanced cancer patients. Dignity therapy in addition to
routine clinical care was not shown to statistically im-
prove the quality of life of these patients as compared to
routine care only. There was symptom improvement in
anxiety levels of the patients studied Fig. 4.
Palliative care in advanced cancer patients i.e. stage 3
or 4, aside from relieving distressing physical symptoms
is aimed at improving quality of life. Quality of life is a
multi-dimensional concept that looks at a patient holis-
tically i.e. physical, psychological and spiritual aspects.
Few RCT’s to date have been conducted on DT. Previ-
ous studies on DT focused on relieving distress symp-
toms as well as anxiety and depression among other
symptoms (Fig. 5). Only one assessed quality of life as a
primary outcome and even then no marked improve-
ment was seen [9]. This study showed improved anxiety
symptoms with a trend towards significance (p = 0.059)
in the DT group and this mirrors the study done by
Juliao et al. that showed that DT was associated with
lower depression scores at up to 2 weeks of follow-up
(p < 0.0001) and lower anxiety (P < 0.0001) within 3
weeks [16, 17]. The study done by Juliao et al. in 2014 is
quite similar to this study with subtle differences. In
similarity, both studies had a similar population with a
mean age of 66.1 in Juliao’s study compared to 51.8 in
this study. Majority of the population were female can-
cer patients on both studies (Fig. 6). Also similar is the
fact that the primary investigators were involved in both
studies and sessions lasted an average of 30 min. A stark
difference in the studies is that Juliao explored other
sociodemographic characteristics which this study did
not e.g. race, marital status, religion and education. In
the Juliao et al. study, it was found that these patients
had high depression and anxiety scores even at baseline
and demonstrated the positive effect of dignity therapy
on these symptoms [16, 17]. The study showed that the
two symptoms were reduced significantly with DT as an
intervention. This AKUHN study also explored baseline
anxiety scores and found that though not marked, they
were significantly improved by Dignity therapy (p =
0.059) showing a trend towards significance. The choice
to use the ESAS as a tool was its simplicity as shown in
studies with similar designs e.g. Juliao et al (Fig. 7).
The effect on depression and anxiety is expected due to
the nature of the illness, which results in increased anxiety
Fig. 4 below: Box plot showing mean symptom distress scores for intervention group (18.18) and control group on follow-up (26.78).
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Fig. 5 Symptom distress scores for intervention and control groups at followup.
Fig. 6 Frequency graph illustrating distribution of cancer types in study population.
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levels and depression. This has been shown in numerous
studies [16, 17] more so in patients with advanced cancers.
Patients nearing the eminent end of their lives have many
needs in addition to physical ones. Psychological distur-
bances e.g. anxiety, poor social, emotional and cognitive
function have been shown to profoundly affect such pa-
tients more than the physical symptoms. Treatment of
anxiety helps alleviate these distressing symptoms and this
in turn improves quality of life of palliative care patients
[16, 17, 28, 29]. Perhaps dignity therapy provides a means
that patients can address existential issues like unfinished
business and assists them express their long-term desires
hence manifesting as a reduction of anxiety. This is how-
ever merely a speculation and further studies are needed
in this area (Figs. 8 and 9).
With the above, this study shows certain strengths in-
cluding the fact that it is one of two, which attempted to
evaluate effect of DT on quality of life. It is also the only
study done in the subject in Africa thus far. This is im-
portant since palliative care is a neglected area in treat-
ment of advanced cancer patients in Kenya. The need to
incorporate it into clinical care is aligned with the need
of dignity therapy to improve quality of life, more so in
reducing anxiety surrounding advanced cancer manage-
ment (Figs. 10 and 11).
Limitations to this study have been recognized includ-
ing the fact that this study was conducted solely at a
private institution and is not a reflection of the wider
scope of healthcare in Kenya, which is mostly rural, and
resource poor hence may not be applicable these set-
ups. A second limitation is the possibility that this study
may have been underpowered hence not showing statis-
tical significance in the primary outcome. Of note, the
biggest study to date [9] had a sample size of 441 while
this study had 144. This study mirrored the smaller
studies done [12–15, 18–21, 30, 31] which showed a
similar limitation of under powering.
Another area of bias in the study is the use of single
blinding which was a significant limitation.
The third limitation is the short time taken to do the
study in most patients i.e. 30-60 min minutes. The coun-
sellors undertaking the study took about 10 min to es-
tablish rapport between the patients. During this time,
pre-assessment ESAS forms were filled. Could we have
detected a statistical significance in scores had the ses-
sions lasted longer and thus had a larger impact? Per-
haps. This is however controversial since we have seen
from the results that even the limited time given for dig-
nity therapy had a profound effect on Anxiety.
The fourth limitation encountered is in data collection.
Data was mainly from the medical oncology and surgical
oncology clinics. Gynaecology clinics were few. This
could have skewed the results especially in representa-
tion of the common malignancies. Only three persons
Fig. 7 Frequency graph illustrating distribution of cancer types in Male population.
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Fig. 9 Bar graph illustrating distribution of cancer types according to age.
Fig. 8 Frequency graph illustrating distribution of cancer types in female population
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Fig. 10 Frequency graph illustrating distribution of comorbidities in study population.
Fig. 11 Bar graph illustrating distribution of comorbidities according to sex.
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conducted the intervention (Dignity therapy) i.e. the
principal investigator and two professional counsellors.
It was difficult to recruit other professionals due to lim-
ited funds and strict institutional policies. More
personnel are needed in future studies. In addition, we
do recognise that different counsellors approach subject
matter differently; this could have been a major negative
influence in the study since standardisation of counsel-
ling technique is difficult.
It is also important to note that the ESAS-r document
though validated in the west has not been validated in
our population. This could have limited its use in our in-
digenous population though patients accessing AKUHN
are cosmopolitan.
Stigma facing the terminally ill patients was also an
important limitation in this study. Many patients de-
clined involvement due to fear of stigma. Many who
went through the therapy reported feeling as though it
was a “death sentence”. Patients need to be educated on
the benefits of dignity therapy and this should be insti-
tuted early in their care.
Lastly, this Study focused on some aspects of quality
of life, which comprised of nine symptoms from the
ESAS. It did not assess other aspects e.g. financial as-
pects, distress and dying concepts, hope, boredom, per-
formance etc. Future studies need to be done to
incorporate the above.
Conclusion
Despite having had no statistical effect on the overall
quality of life score, there was clinical improvement in
follow-up summated symptom scores as from some pre-
vious studies [23, 24]. This improvement in summated
symptom score in the DT group compared to the con-
trol group is a good indicator of quality of life. In
addition, symptom scores of anxiety showed a trend to-
wards significance p = 0.059.
Therefore, incorporating dignity therapy in clinical
care more so in palliative patients (especially those with
anxiety) with advanced cancers may be beneficial. Due
to the limitation of sample size and under powering, a
larger study should be conducted on this subject. Fur-
ther studies should also incorporate the patients’ socio-
demographic factor so as to capture a larger model of
quality of life.
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